3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
61
Stomach Neoplasms
46
Colorectal Neoplasms
24
Esophageal Squamous Cell Carcinoma
19
Rectal Neoplasms
11
Esophageal Neoplasms
11
Pancreatic Neoplasms
7
Cholangiocarcinoma
6
Liver Neoplasms
5
Colonic Neoplasms
4
Neoplasms
3
Colorectal Cancer Metastatic
3
Spinocerebellar Degenerations
2
Neoplasm Metastasis
2
Locally Advanced Rectal Cancer
2
Liver Diseases
2
Gastric Adenocarcinoma
2
Advanced Biliary Tract Cancer
2
Uterine Cervical Neoplasms
1
Unresectable Locally Advanced Pancreatic Cancer
1
Turcot syndrome
1
Tislelizumab
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pancreatic Cancer Resectable
1
Pancreatic Cancer Metastatic
1
PD-1 Antibody
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Microsatellite Stable Metastatic Colorectal Cancer
1
Interventions
sintilimab
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Metastatic Gastric Cancer
×
sintilimab
×
Gastrointestinal
×
Clear all
NCT04089657
2019-09-13
ASGARD
Fujian Cancer Hospital
Phase 2
Unknown
40 enrolled